By RTT News,
January 31, 2014, 06:46:00 AM EDT
(RTTNews.com) - ImmunoGen, Inc. ( IMGN ), a developer of targeted anticancer therapeutics, reported Friday that its second-quarter net income was $3.81 million or $0.04 per share, compared to a net loss of $24.39 million or $0.29 per share last year.
On average, 15 analysts polled by Thomson Reuters expected loss of $0.18 per share for the quarter. Analysts' estimates typically exclude special items.
Revenues were $30.1 million for the quarter, significantly higher than last year's $2.6 million. Analysts expected revenues of $18.16 million.
The company noted that its latest quarter revenues included $25.7 million of license and milestone fees, compared to $0.4 million a year ago.
Looking ahead for the full year, the company continues to project net loss between $67 million and $71 million, and revenues between $71 million and $75 million. Analysts estimate loss per share of $0.74 and revenues of $71.65 million.
Daniel Junius, President and CEO, said, "We expect 2014 to be a very active year. â€¦ We are making solid progress with our IMGN529 compound and expect to report the first clinical data mid-year."
Separately, ImmunoGen announced the appointment of Eric Guempel as Vice President of Product Strategy and Program Management. He reports to Charles Morris, Executive Vice President and Chief Development Officer of ImmunoGen.
For comments and feedback: contact firstname.lastname@example.org